



Washington State Health Care Authority
Prescription Drug Program

P.O. Box 91132 • Seattle, Washington 98111-9232
206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • www.rx.wa.gov

February 26, 2007

Dear Interested Party:

Following recommendations by the Washington State Pharmacy and Therapeutics Committee, the Department of Social and Health Services - Health and Recovery Services Administration (DSHS-HRSA), the Health Care Authority - Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List:

Attention Deficit/Hyperactivity Disorder

Short-Acting Products

methylphenidate HCL§ (Methylin)
dextroamphetamine§
amphetamine salt combination §

Intermediate-Acting Products

methylphenidate ER/SA§
Methylin ER (10 mg)
dextroamphetamine SA§

Long-Acting Products

methylphenidate LA (Concerta®)
amphetamine salt combination
(Adderall XR®)

Non-Stimulant Product

atomoxetine (Strattera®)

§ = generic products only

Each agency will use the common PDL according to its benefit structure, including age and dosing limits.

DSHS-HRSA and UMP will implement the Attention Deficit/Hyperactivity Disorder class on April 1, 2007.

If you have other questions or comments regarding this announcement, please contact Regina Chacon at (206) 521-2027 or by email at pdp@hca.wa.gov.

Sincerely,

Duane Thurman
Director, Prescription Drug Program